Serina Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SER NYSE American 2830 serinatherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Serina Therapeutics, Inc.

Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference - Jul 24th, 2026 4:00 am
Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease - Jul 23rd, 2026 4:00 am
Serina Therapeutics Appoints Farrell Simon to its Board of Directors - Jul 22nd, 2026 2:30 pm
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease - Jul 9th, 2026 10:10 am
Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program - Jun 30th, 2026 7:01 am
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - May 14th, 2026 2:20 pm
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - May 13th, 2026 6:06 am
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit - Apr 7th, 2026 4:00 am
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan - Apr 2nd, 2026 2:13 pm
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights - Mar 25th, 2026 2:20 pm
Serina Therapeutics to Present at the 38th Annual Roth Conference - Mar 24th, 2026 4:00 am
Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease - Mar 18th, 2026 2:10 pm
Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease - Feb 24th, 2026 2:05 pm
Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease - Feb 19th, 2026 4:00 am
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event - Feb 3rd, 2026 4:00 am
Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease - Jan 28th, 2026 2:12 pm
Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity - Jan 15th, 2026 2:30 pm
Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry - Dec 11th, 2025 2:15 pm
Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program - Dec 10th, 2025 2:30 pm
Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights - Nov 13th, 2025 4:10 am